Biovaxys Technol (BVAXF) Stock News

Summary not available.

BioVaxys (OTCQB: BVAXF) reported Phase 1 safety and immunogenicity results for two DPX-formulated cancer vaccines, maveropepimut-S (MVP-S) and DPX-SurMAGE, in 12 patients with recurrent non-muscle invasive bladder cancer (NMIBC) treated prior to transurethral resection.

Both products were well tolerated and induced systemic antigen-specific T cell responses measured by IFN-γ ELISPOT at Days 0, 28, 49 and 109; 55% of MVP-S recipients showed peak responses at Day 28 and 33% of DPX-SurMAGE recipients showed stronger responses at Day 49. The study confirmed multivalent antigen delivery with DPX and supports advancement to further clinical study.

BioVaxys (OTCQB: BVAXF) reported positive Phase 1 results for maveropepimut-S (MVP-S) combined with neoadjuvant letrozole in postmenopausal women with HR+/HER2- stage II-III breast cancer on December 17, 2025. In three patients (Ki-67 >10%) who received two doses of MVP-S and seven weeks of letrozole, median Ki-67 fell from 24% to 6% (ranges 12–43% to 5–8%). One patient showed an 8-fold increase in survivin-specific IFN-γ T cells. Company and investigators plan expanded profiling and a Phase 2 study to evaluate tumor immune modulation.

BioVaxys licensee SpayVac-for-Wildlife (BVAXD) reported peer-reviewed results from a one-year study in the Bavarian Forest showing a single dose of SpayVac reduced fertility to 11% vs 86% in controls in 47 free-ranging red deer monitored with camera traps, GPS collars and fecal progesterone. The liposome-delivered vaccine platform is licensed from BioVaxys and has now shown contraceptive efficacy across three deer species: fallow, white-tailed and red deer.

SpayVac-for-Wildlife has initiated the regulatory submission process for SpayVac targeting feral horses and free-ranging deer; the companies anticipate a potential royalty stream from sales.

BioVaxys Technology Corp. (OTCQB: BVAXF) has announced a 10:1 share consolidation of its common shares, expected to commence trading on September 11, 2025. Following the consolidation, the company's outstanding shares will reduce from 293,425,203 to approximately 29,342,496 shares.

The consolidation will adjust the exercise price and number of shares for outstanding convertible securities proportionally, except for Debenture Warrants. Registered shareholders with physical certificates must submit them along with a transmittal letter to Odyssey Trust Company, while shareholders without physical certificates need not take action.

BioVaxys is a clinical-stage biopharmaceutical company developing immunotherapies, including its DPX™ platform and HapTenix© tumor cell construct platform for treating cancers and other immunological diseases.

BioVaxys Technology Corp. provided a comprehensive corporate update on its operations and strategic initiatives. The company is focusing on integrating assets acquired from IMV Inc. in February 2024, including the DPX immune educating platform. Key developments include out-licensing DPX technology, restarting clinical studies (notably DPX-surMAGE for bladder cancer), and reducing risk through amended milestone provisions with Horizon Technology Finance. BioVaxys is pursuing multiple pipeline expansions through collaborations, including partnerships with AP Visionaries for food allergy treatments and Sona Nanotech for cancer therapeutics. The company's late-stage pipeline includes MVP-S in phase 2b for lymphoma and ovarian cancer, showing promising clinical results. BioVaxys announced a 10:1 share consolidation and is pursuing a private placement to raise between $2-3 million.

BioVaxys Technology Corp has executed an amendment to its Asset Purchase Agreement (APA) with Horizon Technology Finance Corporation regarding the acquisition of IMV Inc's DPX immune educating platform technology assets. The key changes include: 1) Reduction of the performance milestone from USD $10M to USD $2.03M, to be raised by September 30, 2025; 2) Extension of the Licensing Earn-Out Payments Term to August 11, 2033; 3) Issuance of 2.8M warrants to Horizon and 1.2M warrants to Powerscourt at CAD $0.06 per share, exercisable until May 31, 2028. The amendment modifies terms for capital raising requirements and revenue sharing arrangements from licensing agreements.

BioVaxys Technology Corp. (BVAXF) and Sona Nanotech Inc. have entered into a Research Agreement to develop new cancer therapeutics. The collaboration combines BioVaxys' DPX™ Immune Educating Platform with Sona's Targeted Hyperthermia Therapy™ (THT) and Gold Nanorod technology. The research will be conducted at Dalhousie University, evaluating DPX's immune stimulatory properties when used with THT, and exploring DPX as a carrier for novel neoantigens expressed after immunotherapy. In preclinical studies, Sona's THT demonstrated a 100% response rate in immunotherapy-resistant tumors when combined with PD-1 inhibition. The collaboration costs will be covered by the Giacomantonio Immuno-Oncology Research Group, with both companies co-owning any developed therapeutics.

BioVaxys Technology Corp. (BVAXF) and SpayVac for Wildlife have expanded their License Agreement to include commercial aquaculture and farm-raised fish markets. The expansion targets a significant market opportunity in farm-raised Atlantic salmon and rainbow trout, with an annual harvest of approximately 3.28 million metric tons (800 million individual fish).

SpayVac's single-dose fertility-control vaccines offer an alternative to triploidy in aquaculture, with initial proof-of-concept trials progressing to the second phase. The technology uses a patented liposome-based delivery platform, demonstrating 4-10 years of contraceptive efficacy in various species.

The company is pursuing regulatory approval for feral horses and free-ranging deer populations, with the U.S. Bureau of Land Management (BLM) as a potential lead customer. The BLM currently manages 53,797 horses on the range, significantly above the Appropriate Management Level of 22,637, spending 66% of its $153 million budget on long-term holding costs.